FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 256 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Great Oaks Grow From Small Acorns Oncology Is Committed to Doing... September 9, 2022 Heine H. Hansen Award: Johan Vansteenkiste and Fiona Blackhall Honoured for... March 11, 2021 The Frontline Oncology Workforce Unites to Reduce the Burden of Cancer... September 9, 2022 EMA Recommends Extension of Therapeutic Indications for Enzalutamide March 28, 2024 Load more HOT NEWS Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with... Study Suggests that Cancer Patients Who Eat Peanuts Frequently May Be... ScottishPower supports vital research into air pollution and cancer Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer
